McKesson Corporation
MCK Healthcare Medical Distribution
McKesson Corporation’s revenue for fiscal 2026 (year ended March 2026) was $403.4 billion, up 12.4% from fiscal 2025.
- Revenue
- +7.57%
- EPS
- +17.0%
- Free cash flow
- +32.5%
- Total debt
- +7.08%
Quarter to September 2026, against a year earlier
Follow MCK
Alert me
McKesson Corporation (MCK) P/E ratio
As of 5 November 2026, McKesson Corporation (MCK) trades at a P/E ratio of 27.5×. Over the past ten years it has ranged from 0.0× (December 2021) to 1,687× (June 2019); the current reading is higher than 73% of that period. That is above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 22.4× | (13.61%) |
| FY2025 | 25.9× | 8.87% |
| FY2024 | 23.8× | 68.47% |
| FY2023 | 14.1× | (66.29%) |
| FY2022 | 41.9× | — |
| FY2021 | 0.0× | — |
| FY2020 | 26.1× | (98.25%) |
| FY2019 | 1,486× | 144.38% |
| FY2018 | 608× | 9,559.61% |
| FY2017 | 6.3× | (60.74%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 21.9× | 8.60% |
| Jun 2026 | 20.1× | (10.10%) |
| Mar 2026 | 22.4× | (4.66%) |
| Dec 2025 | 23.5× | (1.88%) |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| COR Cencora, Inc. compare | 18.8× |
| HSIC Henry Schein, Inc. compare | 22.8× |
| MCK McKesson Corporation | 27.5× |
| CAH Cardinal Health, Inc. compare | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on MCK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement